Skip to main content
. 2012 Dec 20;7(12):e48729. doi: 10.1371/journal.pone.0048729

Table 1. Phenotype of large-scale expanded TIL from melanoma-invaded lymph nodes of 47 patients treated by TIL.

Patients Relapse-free survivalc % CD2-positiveb % CD3-positiveb % CD3/CD4-positiveb % CD3/CD8-positiveb % CD3/CD25-positiveb
E1a E2 E1 E2 E1 E2 E1 E2 E1 E2
M88* + ND ND 100 100 27 39 71 56 ND 19
M110 −(7) 100 99 99 99 78 84 18 18 51 40
M113 −(6.5) 100 100 99 100 36 75 63 28 9 42
M117 + 100 100 100 100 30 3 70 97 41 14
M125 −(3) 100 100 99 100 71 65 30 36 56 27
M131 −(5) 100 100 100 100 35 40 62 57 38 60
M132 −(2) 100 100 100 100 39 20 58 80 45 27
M134 + 100 100 100 100 55 62 45 38 25 22
M140 + 100 100 100 100 81 81 19 19 30 22
M153 −(3) 100 100 100 100 34 35 61 56 12 19
M154* −(156) 100 100 100 100 59 63 40 39 12 17
M158 −(5) 100 100 100 100 30 31 70 63 9 16
M164 −(26) 100 100 100 100 60 61 38 39 28 14
M167 −(4) 100 100 100 100 24 18 74 79 15 12
M170* + 100 100 100 100 30 32 67 67 16 36
M171 −(3) 100 100 100 100 48 42 52 58 19 11
M177* + 100 100 100 100 42 63 56 32 34 24
M182 + 100 100 100 100 87 25 13 71 54 31
M187 + 100 100 100 100 16 24 86 76 5 10
M193 −(4) 100 100 100 100 14 27 86 73 7 15
M196* −(6) 100 100 100 100 40 22 58 74 17 8
M197* + 100 100 100 100 48 32 52 68 13 14
M199 −(2) 100 100 100 100 25 14 75 86 33 19
M200 −(7) 100 100 100 100 38 37 42 57 11 16
M204 −(3) 100 100 100 100 92 88 8 17 11 7
M212 −(8) 100 100 99 98 52 33 47 57 13 13
M218* + 99 100 100 100 44 5 55 96 ND ND
M234* −(26) 100 100 100 100 62 49 42 51 ND ND
M241* −(13) 100 100 100 100 2 25 99 75 ND ND
M245* −(8) 100 100 100 100 32 26 68 74 ND ND
M252* −(2) 100 ND 100 ND 26 ND 71 ND ND ND
M254* + 100 100 100 100 13 19 87 78 16 37
M263* −(14) 100 100 100 100 22 30 77 68 11 5
M275* −(8.5) 99.95 99.9 99.9 99.8 14.45 19.9 85.57 79.78 20.62 4.43
M278* + 99.93 99.98 99.84 99.87 6.11 4.8 93.17 93.91 2.02 2.26
M284* + 99.98 99.95 99.97 99.99 63.94 53.89 37.7 59.25 7.75 18.12
M288* + 99.97 99.95 100 99.71 34.48 59.72 65.07 57.73 8.88 8.56
M301* −(6) 99.93 99.99 99.74 99.92 24.43 30.64 72.44 66.83 2.06 3.22
M305* + 99.98 99.92 99.93 100 19.1 20.08 80.9 79.99 6.22 2.97
M314* −(3.5) 99.9 99.94 97.64 98.86 62.64 61.72 32 34.36 6.92 16.74
M329* −(27) 99.86 100 98.63 99.45 34.65 39.97 62.88 57.22 16.2 13.09
M379* −(4) 99.9 99.9 100 99.9 31.2 29.9 68.8 71 18.4 6.4
M386* + 99.8 98.9 98.5 98.8 71.4 69.4 27.7 26.3 41.6 26
M415* + 99.7 100 92 84.1 51.4 42.7 40.2 41.3 18.3 43.7
M417* + 99.9 99.8 97.6 95.8 19 36.1 68.6 56.1 11.8 10.3
M424* + 99.5 99.9 99.9 99.9 41.7 44 57.2 50.4 6.2 6.2
M428* + 99.6 99.4 99.9 99.7 54.3 36.9 44.4 57.2 20.2 5.2
*

Melanoma patients bearing only one metastatic lymph node (early stage III patients).

a

E1 and E2 were TIL populations obtained and reinjected to the patient from respectively the first and the second ex-vivo expansions.

b

Percentages of CD-positive TIL were estimated by membrane labeling. Cells were analyzed on a FACScalibur.

c

Relapse-free survival of patients (−): patients who relapsed,(months); (+): patients who did not relapse.